Gender (N, %) |
|
|
|
|
|
Female |
2 (13.3 %) |
7 (21.2%) |
0.52 |
1 |
Reference |
Male |
13 (86.7%) |
26 (78.8%) |
- |
1.75 |
0.32-9.64 |
CD4+ T cell count per µL at T0 (N, %) |
|
|
|
|
|
<500 per µL |
2 (13.3%) |
5 (15.2%) |
0.87 |
1 |
Reference |
>500 per µL |
13 (86.7%) |
28 (84.6%)) |
- |
1.16 |
0.20-6.79 |
CD4+ T/CD8 ratio >=1 at T0 (N, %) |
|
|
|
|
|
No |
7 (46.7%) |
18 (54.5%) |
0.61 |
1 |
Reference |
Yes |
8 (53.5%) |
15 (45.5%) |
- |
1.37 |
0.40-4.66 |
CD4+ T/CD8 ratio >=0.4 at T0 |
|
|
|
|
|
No |
1 (6.7%) |
6 (18.2%) |
0.32 |
1 |
Reference |
Yes |
14 (93.3%) |
27 (81.8%) |
- |
3.11 |
0.34-28.5 |
OIR at T0 |
|
|
|
|
|
No |
10 (66.7%) |
19 (57.6%) |
0.56 |
1 |
Reference |
Yes |
5 (33.3%) |
14 (42.4%) |
- |
0.68 |
0.19-2.43 |
Positive anti-N T0 |
|
|
|
|
|
No |
13 (86.7%) |
28 (84.6%) |
0.87 |
1 |
Reference |
Yes |
2 (13.3%) |
5 (15.2%) |
- |
0.87 |
0.15-5.04 |
Positive anti-N T3 |
|
|
|
|
|
No |
14 (93.3) |
28 (84.6%) |
0.42 |
1 |
Reference |
Yes |
1 (6.7%) |
5 (15.2%) |
- |
0.4 |
0.04-3.76 |
Positive anti-N T6 |
|
|
|
|
|
No |
13 (86.7%) |
27 (81.8%) |
0.68 |
1 |
Reference |
Yes |
2 (13.3%) |
6 (18.2%) |
- |
0.70 |
0.12-3.91 |
Positive anti-N T1c |
|
|
|
|
|
No |
12 (80%) |
25 (75.8%) |
0.75 |
1 |
Reference |
Yes |
3 (20%) |
8 (24.2%) |
- |
0.78 |
0.18-3.48 |
Anti-S titre T1b, U/mL |
|
|
|
|
|
< 2,500 |
8 (53.3%) |
13
(39.4%) |
0.59 |
1 |
Reference |
2,500 - 7,500 |
5 (33.3%) |
13 (39.4%%) |
- |
0.62 |
0.12-2.43 |
>7,500 - <12,500 |
1 (6.7%) |
1 (3%) |
- |
1.62 |
0.09-29.78 |
>12,500 |
1 (6.7%) |
6 (18.2%) |
- |
0.30 |
0.03-2.68 |
ND50 T1b |
|
|
|
|
|
<1000 |
4 (26.7%) |
12 (36.4%) |
0.82 |
1 |
Reference |
1000-2500 |
7 (46.7%) |
8 (24.2) |
- |
2.63 |
0.57-12 |
2500-5000 |
2 (13.3%) |
5 (15.2%) |
- |
1.2 |
0.16-8.8 |
>5000 |
2 (13.3%) |
8 (24.2%) |
- |
0.75 |
0.11-5.1 |
Blips before vaccination |
|
|
|
|
|
No |
9 (60%) |
28 (84.6%) |
0.06 |
1 |
Reference |
Yes |
6 (40%) |
5 (15.2%) |
- |
3.73 |
0.92-15.2 |